RT Journal Article
SR Electronic
T1 600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A683
OP A683
DO 10.1136/jitc-2023-SITC2023.0600
VO 11
IS Suppl 1
A1 Kilickap, Saadettin
A1 Sezer, Ahmet
A1 Gümüş, Mahmut
A1 Bondarenko, Igor
A1 Özgüroğlu, Mustafa
A1 Gogishvili, Miranda
A1 He, Xuanyao
A1 Gullo, Giuseppe
A1 Rietschel, Petra
A1 Quek, Ruben GW
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A683.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.